Expansion of Lonza’s Automated Robotic Solution for Endotoxin Testing Automates Sustainable Recombinant Factor C Assay

12 Apr 2021 Downloads News Release PDF The PyroTec® PRO Automated Solution combined with the PyroWave® Reader option expands the range of endotoxin testing types available on the platform to now include the PyroGene® Recombinant Factor C assay The addition of the PyroWave® XM Fluorescent Reader complements the existing absorbance readers used in traditional LAL-based assays Full integration with... Read more

Lonza’s Fully Automated Plate-Based Robotic Solution Enables Simple, Fast and Reliable Endotoxin Detection

April 25,2019 Product News pdf Walkersville, MD (USA) / Basel (CH), 25 April 2019 – Lonza today announced the global availability of the world’s first fully automated and integrated plate-based PyroTec™ PRO Robotic Solution for endotoxin testing. Combining the speed and reproducibility of a robotic liquid handling platform with the power of version 6.0 of Lonza’s market-leading WinKQCL™ Software,... Read more

Lonza to Launch the MODA™ ES Next-Generation Electronic Batch Record Execution Platform at the Paperless Lab Academy 2019

Walkersville, MD (USA) / Basel (CH), 3 April 2019 – Lonza will launch the MODA™ ES Software Platform, a next-generation electronic batch record execution solution, at the Paperless Lab Academy 2019 from 9-10 April at Baveno, Lake Maggiore (IT). Building on Lonza’s extensive informatics know-how and contract manufacturing expertise, the new platform offers a flexible and... Read more

Lonza Launches GS piggyBac™ – A Unique and Versatile Cell Line Engineering Technology

March 27,2019 Product News PDF •  Combining piggyBac™ transposon technology with Lonza’s GS Xceed® expression system results in stable CHO pools with high levels of recombinant protein expression •  The GS piggyBac™ system offers benefits for bioprocessing, particularly for challenging low-expressing proteins, helping to generate high-performing pools for material supply •  Ability to insert large amounts... Read more

Lonza Establishes Custom Cell Biology Services to Offer Unique Manufacturing and Testing Capabilities

Walkersville, MD (USA) / Basel (CH), 27 March 2019 – Lonza has introduced CellBio Services, a comprehensive portfolio of unique, custom solutions designed to meet specific, individual research application needs. Researchers across pharmaceutical and contract manufacturing organizations can now choose from an extensive range of services, including cell-line expansion and banking, media production, cell isolation,... Read more

Lonza Expands Mycoplasma Detection Portfolio with New Luminometer Designed to Accelerate and Simplify Testing

Walkersville, MD (USA) / Basel, Switzerland, 14 March 2019 – Lonza has further strengthened its extensive mycoplasma detection portfolio with the addition of the Lucetta™ 2 Luminometer, a single-tube system designed to simplify and accelerate mycoplasma detection in cell cultures. Pharmaceutical, biotechnology and academic researchers can now rely on this compact, portable and easy-to-use instrument to... Read more

Lonza’s New Spheroid-Forming Human Hepatocytes Facilitate Improved In Vitro Liver Model Systems

Walkersville, MD (USA) / Basel (CH), 4 March 2019 – Lonza has further expanded its hepatocytes portfolio characterization with the addition of Verified for Spheroids™ Human Hepatocytes, which are pre-screened for their ability to promote rapid spheroid formation in cell culture. Researchers working in toxicology, disease modeling and DMPK studies can now feel more confident... Read more

Lonza Completes Divestment of Water Care Business

March 01,2019 NEWS RELEASE PDF Basel (CH), 1 March 2019 – Lonza announced today the completion of the divestment of its former Water Care business and operations to Platinum Equity for USD 630 million. The strategic agreement between both parties was already announced on 1 November 2018. Lonza plans to re-invest parts of the proceeds of the Water... Read more

Lonza’s New Pooled Donor Suspension Hepatocytes Enable the Next Level of Reliability, Robustness and Customizability

Walkersville, MD (USA) / Basel, Switzerland, 11 February 2019 – Lonza announces the launch of DonorPlex™ Hepatocytes, a new line of high-quality cryopreserved pooled donor suspension hepatocytes, which are the first of their kind to be produced using Lonza’s novel patented manufacturing process. Researchers within DMPK and ADME laboratories can now benefit from this reliable... Read more

Lonza and AllCells Join Forces for Global Commercialization of Hematopoietic Primary Cells

Walkersville, MD (USA) / Basel (CH), 7 February 2019 – Lonza and AllCells have entered into a private label partnership for the manufacture and global commercialization of an extensive range of hematopoietic primary cells. This partnership expands Lonza’s broad offering of hematopoietic cell lines and enables cell biologists to easily access a wide selection of... Read more